Multiplex Assay Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay)

CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 88-98 95
EDTA plasma(n=5) 78-96 81
heparin plasma(n=5) 95-104 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-101% 84-93% 78-94% 94-102%
EDTA plasma(n=5) 86-94% 89-96% 80-104% 91-105%
heparin plasma(n=5) 78-90% 94-101% 96-103% 86-94%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:VEGFR2) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
APMIS Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway PubMed: 23398358
Acta Biomater Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study PubMed: 26689470
Acta Biomaterialia Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study Pubmed:26689470
Journal of Cellular Physiology A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells. pubmed:27925188
Regenerative Biomaterials The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic 10.1093/rb/rbx028
International Journal of Immunopathology and Pharmacology VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these … Pubmed:29985074
JOURNAL OF DERMATOLOGICAL TREATMENT Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris Pubmed: 32043381
Journal of Genetic Engineering and Biotechnology Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells 33523322
Mol Cell Biochem Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy 34324118
BMC Nephrol Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys Pubmed:35643467
Catalog No. Related products for research use of Ovis aries; Ovine (Sheep) Organism species Applications (RESEARCH USE ONLY!)
SEB367Ov ELISA Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB367Ov Multiplex Assay Kit for Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.